Stocksigma LogoStocksigma Logo

Emcure Pharmaceuticals: CARE Ratings Reaffirms Credit Ratings

CARE Ratings reaffirmed its credit ratings for Emcure Pharmaceuticals on 01 Sep'26, citing a healthy business profile

Emcure Pharmaceuticals: CARE Ratings Reaffirms Credit Ratings

Emcure Pharmaceuticals Ltd · Others (Uncategorized) · 01 Sept 2026, 9:14 pm

Emcure Pharmaceuticals: CARE Ratings Reaffirms Credit Ratings CARE Ratings reaffirmed its credit ratings for Emcure Pharmaceuticals on 01 Sep'26, citing a healthy business profile. Ratings include 'CARE AA; Stable' for long-term facilities (enhanced to ₹785.00 crore) and 'CARE A1+' for short-term facilities (₹52.00 crore). In FY26, revenue grew ~18% YoY to ₹9,322 crore, driven by international markets. The PBILDT margin improved to 20.0% from 18.7% in FY25. Debt protection metrics remain comfortable, with TD/PBILDT at 0.81x, despite total debt rising to ₹1,519 crore.

Original exchange filing (PDF)

More announcements from Emcure Pharmaceuticals Ltd

All Emcure Pharmaceuticals Ltd announcements